BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33938028)

  • 1. Clinical relevance of serum immunoglobulin G4 in glucocorticoid therapy of Graves' ophthalmopathy.
    Li Y; Luo B; Zhang J; Zhou X; Shao S; Xu W; Yang Y; Yuan G
    Clin Endocrinol (Oxf); 2021 Oct; 95(4):657-667. PubMed ID: 33938028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
    Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of extraocular muscles in Graves' ophthalmopathy using T1 mapping.
    Zhu H; Zou M; Wu D; Li B; Su Y; Li Y; Hong S; Yang Z
    Eur Radiol; 2023 Dec; 33(12):9074-9083. PubMed ID: 37466707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Manifestations and Clinical Implications of Serum Immunoglobulin G4 Levels in Graves' Ophthalmopathy Patients.
    Luo B; Yuan X; Wang W; Zhang J; Liu R; Hu W; Qi X; Xiang N; Chen L
    Ocul Immunol Inflamm; 2022 Apr; 30(3):580-587. PubMed ID: 33054491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Immunoglobulin G4 levels are elevated in patients with Graves' ophthalmopathy.
    Bozkirli E; Bakiner OS; Ersozlu Bozkirli ED; Eksi Haydardedeoglu F; Sizmaz S; Torun AI; Ertorer ME
    Clin Endocrinol (Oxf); 2015 Dec; 83(6):962-7. PubMed ID: 25400133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves' ophthalmopathy.
    Hou K; Ai T; Hu WK; Luo B; Wu YP; Liu R
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):938-942. PubMed ID: 29270757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.
    Ahn HY; Lee JK
    J Korean Med Sci; 2020 Jun; 35(23):e177. PubMed ID: 32537950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgG4 as a Biomarker in Graves' Orbitopathy.
    Olejarz M; Szczepanek-Parulska E; Dadej D; Sawicka-Gutaj N; Domin R; Ruchała M
    Mediators Inflamm; 2021; 2021():5590471. PubMed ID: 34220335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
    De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
    Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG4 serum levels in Graves' orbitopathy.
    Comi S; Lanzolla G; Cosentino G; Maglionico MN; Posarelli C; Menconi F; Santini F; Elisei R; Marinò M
    J Endocrinol Invest; 2024 Jul; 47(7):1711-1717. PubMed ID: 38127192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High IgG4 serum concentration is associated with active Graves orbitopathy.
    Olejarz M; Szczepanek-Parulska E; Ostałowska-Klockiewicz A; Antosik P; Sawicka-Gutaj N; Helak-Łapaj C; Stopa M; Ruchala M
    Front Endocrinol (Lausanne); 2023; 14():1083321. PubMed ID: 36936165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
    Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
    Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
    Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
    Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
    [No Abstract]   [Full Text] [Related]  

  • 17. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
    Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.